Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesPreferred Dividend PaymentsProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Ani Pharmaceuticals (ANIP) Other Operating Expenses: 2009-2024

Historic Other Operating Expenses for Ani Pharmaceuticals (ANIP) over the last 16 years, with Dec 2024 value amounting to $312.2 million.

  • Ani Pharmaceuticals' Other Operating Expenses fell 100.37% to -$295,000 in Q3 2025 from the same period last year, while for Sep 2025 it was $291.3 million, marking a year-over-year increase of 3.45%. This contributed to the annual value of $312.2 million for FY2024, which is 32.71% up from last year.
  • Per Ani Pharmaceuticals' latest filing, its Other Operating Expenses stood at $312.2 million for FY2024, which was up 32.71% from $235.2 million recorded in FY2023.
  • In the past 5 years, Ani Pharmaceuticals' Other Operating Expenses ranged from a high of $312.2 million in FY2024 and a low of -$48.8 million during FY2020.
  • In the last 3 years, Ani Pharmaceuticals' Other Operating Expenses had a median value of $235.2 million in 2023 and averaged $246.5 million.
  • Its Other Operating Expenses has fluctuated over the past 5 years, first slumped by 144.32% in 2020, then spiked by 2,296.88% in 2022.
  • Yearly analysis of 5 years shows Ani Pharmaceuticals' Other Operating Expenses stood at -$48.8 million in 2020, then spiked by 82.07% to -$8.8 million in 2021, then soared by 2,296.88% to $192.2 million in 2022, then increased by 22.37% to $235.2 million in 2023, then soared by 32.71% to $312.2 million in 2024.